Results 21 to 30 of about 19,639 (215)

Antiphospholipid Syndrome and Antibodies [PDF]

open access: yesJournal of Immunology Research, 2014
Antiphospholipid syndrome is an acquired thrombophilia characterized by venous or artery thrombosis sometimes accompanied by thrombocytopenia in the presence of antiphospholipid antibodies. The 14th International Antiphospholipid Antibodies Congress was combined with the 4th Latin American Congress on Autoimmunity and took place in Rio de Janeiro in ...
Jozélio Freire de Carvalho   +2 more
openaire   +3 more sources

A role for uric acid and the nalp3 inflammasome in antiphospholipid antibody-induced IL-1β production by human first trimester trophoblast [PDF]

open access: yes, 2013
Women with antiphospholipid syndrome (APS) are at risk of recurrent pregnancy loss and obstetrical disorders, such as preeclampsia and intrauterine growth restriction (IUGR).
Vikki M Abrahams   +13 more
core   +1 more source

Antiphospholipid Antibody Syndrome: Pathogenesis, Diagnosis, and Management in Pregnancy

open access: yesMaternal-Fetal Medicine, 2019
. Antiphospholipid antibody syndrome is an autoimmune disorder that primarily affects reproductive age women and poses significant obstetric complications.
Raminder Kaur Khangura   +3 more
doaj   +1 more source

Budd-Chiari Syndrome as an Initial Presentation of Antiphospholipid Syndrome in a Male [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2022
In Budd-Chiari Syndrome (BCS) there is narrowing and obstruction of the veins of the hepatic veins. Patients have upper quadrant abdominal pain, hepatomegaly and/or ascites.
Pusala Varun Narayana   +3 more
doaj   +1 more source

The Issue of the Antiphospholipid Antibody Syndrome. [PDF]

open access: yesJ Clin Med Res, 2020
Antiphospholipid antibody syndrome (APS) is a state of hypercoagulability secondary to an autoimmune disorder. It is associated with thrombotic events in venous and arterial vessels, obstetric complications characterized by recurrent fetal losses, and increased perinatal morbidity.
Oliveira DC, Correia A, Oliveira C.
europepmc   +4 more sources

Retinopathy in lupus transitioned to Kikuchi-Fujimoto disease

open access: yesAmerican Journal of Ophthalmology Case Reports, 2016
Purpose: We present a patient with systemic lupus erythematosus with significant vaso-occlusive retinal findings mimicking antiphospholipid antibody syndrome, who developed Kikuchi-Fujimoto disease.
Kelly S. Rue   +2 more
doaj   +1 more source

Patient-derived anti-β2GP1 antibodies recognize a peptide motif pattern and not a specific sequence of residues

open access: yesHaematologica, 2017
Antiphospholipid antibody syndrome is an autoimmune disease characterized by the presence of so-called antiphospholipid antibodies and clinical manifestations such as recurrent thromboembolic or pregnancy complications.
Philippe de Moerloose   +5 more
doaj   +1 more source

Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers. [PDF]

open access: yesPLoS ONE, 2017
The non-criteria neuropsychiatric manifestations of antiphospholipid syndrome include headache, dizziness, vertigo, seizure, depression and psychosis. There were still no objective methods qualified to detect the early central nervous system involvement ...
Ting-Syuan Lin   +10 more
doaj   +1 more source

Antiphospholipid Syndrome: A Review

open access: yesHaematology Journal of Bangladesh, 2020
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetric morbidities in the setting of persistently positive levels of antiphospholipid antibodies.
Md. Motahar Hossain   +3 more
doaj   +1 more source

Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients

open access: yesRMD Open
Introduction Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent venous and/or arterial thrombosis.
Zahir Amoura   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy